Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 620.66 Delayed Data As of Aug 07 |  -0.55 / -0.09%Today’s Change | 271.37 Today|||52-Week Range 664.64 | +65.30% Year-to-Date |
Latest REGN News | Press Releases
| Merck to Begin Pivotal COVID-19 Antiviral Studies in September Jul 31 / MotleyFool.com - Paid Partner Content | Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players Jul 28 / Seeking Alpha - Paid Partner Content |
| Regeneron teams up with BioNTech in melanoma Jul 31 / Seeking Alpha - Paid Partner Content | Biotech Bonanza - Second Half Outlook Jul 28 / Seeking Alpha - Paid Partner Content |
| Roche's Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients (Again) Jul 29 / MotleyFool.com - Paid Partner Content | Will Regeneron Help Win the Fight Against COVID-19? Jul 28 / MotleyFool.com - Paid Partner Content |
| Regeneron lands BARDA contract for Ebola cocktail Jul 29 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 621.21 |
| Today’s open | 626.75 |
| Day’s range | 614.76 - 627.00 |
| Volume | 26,834 |
| Average volume (3 months) | 1,215,784 |
| Market cap | $64.7B |
Data as of 4:00pm ET, 08/07/2020
Growth & Valuation
| Earnings growth (last year) | -14.46% |
| Earnings growth (this year) | +10.36% |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +17.18% |
| P/E ratio | 24.1 |
| Price/Sales | 5.47 |
| Price/Book | 6.29 |
Competitors
Data as of 4:00pm ET, 08/07/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | $7.26 |
| Annual revenue (last year) | $7.9B |
| Annual profit (last year) | $2.1B |
| Net profit margin | 26.91% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
